SWOG Cancer Research Network
Two years after starting treatment, patients with stage 3-4 classic Hodgkin lymphoma treated with nivolumab plus AVD chemotherapy had roughly one-half the risk of progression or death of those who had a standard treatment of brentuximab vedotin plus AVD.
“This new analysis with more patient follow-up is critical to understanding the clinically meaningful benefit obtained from N-AVD compared to BV-AVD,” said Michael LeBlanc, PhD, lead biostatistician on the S1826 study and a UW professor of biostatistics.
Category
Teaser Image